Session » Posters: Clinical and Therapeutic Aspects II

Date: Friday, March 20, 2026

Time: 5:00PM-6:00PM

Meeting: 2026 Pediatric Rheumatology Symposium

5:00PM-6:00PM: Abstract Number: 087

A Growing Problem: Factors Associated with Growth Disturbances in Juvenile Localized Scleroderma

5:00PM-6:00PM: Abstract Number: 096

Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study

5:00PM-6:00PM: Abstract Number: 103

Anifrolumab Use in Youngsters with Rheumatic Conditions: Case Series and a Review of the Evidence Base

5:00PM-6:00PM: Abstract Number: 086

APOL1 Focal Segmental Glomerulosclerosis Requiring Renal Transplant, the Burden of Childhood onset Autoimmune and Autoinflammatory Disease

5:00PM-6:00PM: Abstract Number: 112

Burden of Latent and Active TB in Pediatric TNF-Inhibitor Therapy: A Decade of Real-World Data from a Tertiary Care Centre

5:00PM-6:00PM: Abstract Number: 090

Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis

5:00PM-6:00PM: Abstract Number: 106

Clinical Characteristics and Safety Outcomes in Refractory Kawasaki Disease Treated with Second-Dose Infliximab

5:00PM-6:00PM: Abstract Number: 099

Clinical Features of Juvenile Antisynthetase Syndrome: A Single-Center Case Series

5:00PM-6:00PM: Abstract Number: 088

Demographics and Clinical Features of Deficiency of adenosine deaminase 2: A Large Quaternary Single Center Experience

5:00PM-6:00PM: Abstract Number: 084

Early Life Exposures and Risk of Spondyloarthritis: A Population-Based Case-Control Study

5:00PM-6:00PM: Abstract Number: 097

Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

5:00PM-6:00PM: Abstract Number: 100

Experience with Janus Kinase Inhibitors and Abatacept in Juvenile Dermatomyositis: A Retrospective Study from a Large Tertiary Center

5:00PM-6:00PM: Abstract Number: 108

Gender Diverse Youth Treatment Response to Amplified Musculoskeletal Pain Syndrome Rehabilitation

5:00PM-6:00PM: Abstract Number: 093

HOW DO WE HANDLE STILL’S DISEASE? REAL-LIFE CLINICIANS’ CHOICES FROM THE METAPHOR PROJECT WORLDWIDE SURVEY

5:00PM-6:00PM: Abstract Number: 110

Juvenile Idiopathic Inflammatory Myopathies and Macrophage Activation Syndrome: A Case Series

5:00PM-6:00PM: Abstract Number: 082

Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis

5:00PM-6:00PM: Abstract Number: 085

Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?

5:00PM-6:00PM: Abstract Number: 111

Pediatric chronic nonbacterial osteomyelitis outcomes after NSAID or TNF inhibitor discontinuation, a registry cohort with two year follow up data

5:00PM-6:00PM: Abstract Number: 102

Positive Affect and Emotion Regulation Protect Juvenile-Onset Lupus and Dermatomyositis Patients from Emotional Distress: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study Parent-Reported Resiliency Data

5:00PM-6:00PM: Abstract Number: 091

Psychosocial Burden in Juvenile Systemic Sclerosis: Insights from PedQL Outcomes

5:00PM-6:00PM: Abstract Number: 083

Relative Risk of a Thrombotic Event in Janus Kinase Inhibitor Use for JIA using the Epic Cosmos Database

5:00PM-6:00PM: Abstract Number: 095

Rheum2Fake: Lessons from Severe Nutritional Deficiencies

5:00PM-6:00PM: Abstract Number: 105

Rheumatological Biomarkers and Symptom Progression in Pediatric Systemic Lupus Erythematosus (SLE)

5:00PM-6:00PM: Abstract Number: 113

Risk Assessment for Pediatric Rheumatic Diseases in Children with a History of Kawasaki Disease: A Long-Term Retrospective Comparative Big Data Cohort Study

5:00PM-6:00PM: Abstract Number: 107

Targeting Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Real-World Emapalumab Experience Spanning 3 Years

5:00PM-6:00PM: Abstract Number: 109

Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study

5:00PM-6:00PM: Abstract Number: 081

Therapeutic Drug Monitoring in Pediatric Rheumatology: A Survey of Providers in North America

5:00PM-6:00PM: Abstract Number: 092

Treatment-Refractory Juvenile Idiopathic Arthritis: Clinical Features and Biologic/Targeted Synthetic DMARD Utilization Patterns in a Single-Center Cohort

« View all sessions from this meeting

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].